Standout Papers

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo f... 2023 2026 202461
  1. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC (2023)
    Tina Cascone, Mark M. Awad et al. Annals of Oncology

Immediate Impact

50 standout
Sub-graph 1 of 25

Citing Papers

Neoadjuvant Chemoimmunotherapy for NSCLC
2024 Standout
Non-small-cell lung cancer
2024 Standout

Works of C. Coronado Erdmann being referenced

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
2023 Standout

Author Peers

Author Last Decade Papers Cites
C. Coronado Erdmann 205 85 62 12 322
R. Pfeiffer 190 15 38 16 353
William Brannon 45 101 60 16 339
S H Foo 108 87 21 12 362
S Hirai 157 44 12 23 312
Li Sun 53 85 54 23 347
Y. K. Kim 150 23 11 16 325
Cataldo D’Amore 184 48 11 10 329
Norma Di Benedetto 217 27 9 8 334
Yoshimitsu Doi 112 12 39 15 336
Ernesto Cason 214 33 13 13 364

All Works

Loading papers...

Rankless by CCL
2026